Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A 6-Month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy


A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy




The purpose of this study is to determine if rifaximin is safe and effective in preventing the recurrence of Hepatic Encephalopathy (HE) in people with liver disease. People who have experienced HE in the past but are currently not having symptoms may be eligible to participate in this study.

Study Status: Active, not recruiting


Condition Intervention Phase
Hepatic Encephalopathy Drug: Rifaximin Phase 3

Verified by Salix Pharmaceuticals April, 2008

Sponsored by: Salix Pharmaceuticals
Information provided by: Salix Pharmaceuticals identifier: NCT00298038

Study Type: Interventional

Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Case Western Reserve/Cleveland Clinic
Cleveland, Ohio 44109
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site